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Abstract: 
Lynch Syndrnm~ is an autosomal dominant condition causing pr~disposition to 
\arious cancers, primarily color~ctal cancer (CRC). This syndrome is caused hy 
mutations in D A mismatch repair (M IR) g~nes . IMR mutations have been pre iously 
identified in the ewtoundland population and the province of cwfoundland and 
Labrador has one of the highest age standardi sed rates of CRC in anada. The 
Newfoundland Colorecta l Cancer Registry ( FCCR) is a population-based regi try of 
CRC cases in cwfoundland from 1999-2003. Patients from the NFC R were screened 
for MMR mutations. 13 pathogenic mutations were identified in 740 ca c in the 
FCCR. TI1is corresponds to an incidence of Lynch Syndrome of 1.8% of CRC cases in 
the NFCCR. In addi tion, all published li terature concerning Lynch yndrome was 
reviewed to con truct and maintain a web-based public catalogue of MMR mutations as a 
resource tor determining the pathogenicity of any variants identified in thi · and future 
works. 
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Chapter 1 
l.llntroduction: 
I . 1.1 Colorecral Can cer: 
Colon:ctal cancer (CRC) is the third most common cancer in Canada with an 
estimatcd incidence of 20,800 cascs {I 3.8° u or all cancer cases) for 2007 {Cancer 
Canada). It is the leading causc or canccr death in non-smokcrs and is second in lethality 
only to lung cancer, with an estimated 8,500 dcaths { 12.2% of all cancer deaths) for 2007 
{Cancer Canada). In the Canadian population, thc overall lifetime risk of developing 
CRC is approx imately 6% (Cancer Canada). It is estimated that upwards of20% of all 
CRCs have a familial component without a clear genetic cause, while around 2-6% arc 
thought to be hereditary {Kemp eta!., 2004). The most common syndromes known to 
cause hereditary CRC arc: Familial Adenomatous Polyposis ( FAP), Lynch Syndrome 
(LS) or Hereditary Non-Polyposis Colorcctal Cancer (HNPCC) and MYH-associated 
polyposis (MAP); a fourth, Familial Colorcctal Cancer Type X, has recently been 
suggested (Lindor eta!., 2005). 
1. 1 . ., flereditarv Cancer Svndromes : 
1.1.2.1 Familial Adcnomatous Polrr)()sis: 
Familial Adcnomatous Polyposis {FA P) is inherited in an autosomal dominant 
pattern. The signature cl inical feature of'FAP is hundreds or thousands of' polyps 
de\ eloping in the late teens or early twenties. Dcvcloping thi s large number or polyps 
- I -
increases an indi\-idual's lir~·time ri ~k or CRC to a ncar certainty. rAP is a very rare 
disease \\'hich accounts for approximately I 0 " or all CRC', but has a pcnetrance of nearly 
100°u (8isgaard eta/., 199-1-) . Cicnnlinc mutations in the tumour suppressor gene 
wlenolllatousj}(J/_rpo.,·t\ coli (.·IP() account for rAP. Depending on the locationol'the 
gcrmline mutation in .·I PC. another phenotype of Attenuated Familial Adenomatous 
Polypo. is (AFAP) may occur. AFAP is a less severe version ofFAP, with fewer polyp 
( 10-IOOs) and a later age ot'CRC onset. Mutations causing AFAP arc generally localised 
to the 5', 3' or exon 9 regions oL-/PC. They do not down regulate the APC protein to the 
same degree as F AP mutations hence the attenuated phenotype (Sieber eta/., 2006 ). 
1.1.2.2 l'vf}'H-associated polrposis: 
MYH-associatcd polyposis (MAP) presents with tens to hundreds of polyps and is 
inherited in an autosomal recessive pattern (AI -Tassan eta/., 2002). MAP accounts for 
less than I% of all CRC. A diagnosis of MAP must first exclude F AP, that is, there must 
be a negative APC mutation result, because of the clinical similarity of a large number of 
polyps. Some MAP CRC patients have been reported with few or no polyps, which can 
overlap with a Lynch Syndrome phenotype (Wang el a/., 2004). MAP is caused by 
mutations in the MYH (AlutY Homologue) gene. Oxidative damage to DNA can cause the 
formation of H-hydroxyguaninc (8-0xoG) from guanine, which pairs with adenine 
instead ofcyto inc. Subsequent D A replication results in the replacement of8-0xoG 
with thymine (Figure 1. 1 ). The MYI I protein forms a trimer with two additional proteins 
to form a complex which is responsible for the removal of adenine that is paired with 
-2-
(c) 
I l 
Deoxynucleotides + 8-oxo-dGTP 
Replication Replication 
r T 1 T r T I f Go l ~- I r T l 1 1 
l 1 l A l U _L I fo.. l l L l fo.. l j_j 
and 
I ,. A 
l r-r r Go I 1 T T rn G 
I I I l I c I I I 
'-... GO 
Fi~:ure 1.1: GO repair system in prokaryotes: Graphical representation of the 8-
hydroxyguanine (GO) repair system in prokaryotes. These three proteins prevent 8-
hydroxyguanine from integrating into DNA post-replication. In normal function, MutY 
removes adenine nucleotides mispaired with 8-hydroxyguanine, MutT removes a 
phosphate group from 8-0xo-dGTP, preventing it from being used in DNA synthesis, 
while MutM excises 8-0xoG from the synthesised DNA strand. 
(www .mun.ca/biochem/courses/41 03/figures/Griffiths/G 19-36c.jpg) 
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~-OxoCI. f\lutations in MY II disrupt thi s r~rnova l r~sulting in the pairing of' X-Oxo(i " ·ith 
A, and in an accumulat ion of' mutations due to Ci --T transversions which, if they occur in 
critical regions of particular g~n~s. may r~su lt in carc inoma. 
I. I.:!. 3 /_ )'llc/i S)'nt!mme: 
Lynch Syndrome ( LS) or I kn.:ditary on-Polyposis Colorcctal C'anc~r (IINPC'l) 
is anothcr autosomal dominant condition that increases an individual's lifetime ri sk of 
developing CRC, as well as a range of extracolonic cancer . Lynch Syndrome is the most 
common inherited colon canc~r syndrome and is thought to account for anywh~rc from 2-
5% of all CRC. LS patients have been reported to have a lifetime risk of 78% for 
developing C'RC. This is likely to be a very rough estimate as different mutations have 
varying pcnctrance and may cau e different cancers, depending which gene is mutated. It 
has been noted previously that mutations is MUll result in CRC, while mutations in 
MSI/2 arc associated with more extra-colonic tumour (Vascn et a/., 2001, Bandipalliam 
et a /., 2004). Colon and rectal cancers arc the primmy cancers in this syndrome but there 
is also increased risk of developing many extra-colonic tumours including 
endometrial/uterine. ga. tric, small boweL pancreas. hepato-biliary, ovarian. kidney, 
ureter. brain and lymphoma (Lynch eta/., 1993). Particularly significant in females is the 
43% lifetime ri sk of developi ng endometrial cancer. Overall, including colorcctaL 
endometrial and the other ext raco lonic cancers, there is a cumulative 90% lifetime risk of 
cancer (Aamio et a /., 1995). Mutations in any one or at least four mismatch repair 
( :Vl :'v1 R) genes an: responsible for this syndrome: .\H/1 I (.Hut L 1/omo/ogue /). JfS/-1:! 
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(.\lutS 1/omo/ogue .?) . . HSI!tS (.\lutS 1/omo/ogue (J) and P.\IS:! (Postmeiotic Segregation 
incrl'<ISC'tf _:> ) . 
/ . / . .? . ./Familial Colorectal Cancer Tme X 
Familial Colorcctal Cancer Type X has been used to describe some l ~1milies who 
match the most stringent familial criteria for Lynch Syndrome, but lack the s igns of a 
MMR dd'cct such as microsatellite instability (sec bdow) or a MMR gene mutation. 
These apparent LS familie arc also noted to have a lower incidence of cancer than LS 
families, fewer extra-colonic tumours and a later age of onset (Lindor eta/. , 2005; Woods 
eta/., 2006). 
1. 1.2.5 Other Colorectal Cancer S!'ndromes: 
Two other rare cancer syndromes, Muir-Torre and Turcot, can also be caused by 
mutations in the MMR genes. Muir-Torrc Syndrome is an autosomal dominant condition 
which was reported independently by Muir eta/. in 1967 and Torre in 196R. The 
syndrome presents with the same cancers as Lynch Syndrome but with additional 
sebaceous cancers of the skin. Muir-Torre Syndrome is caused by mutations in the MMR 
genes MSH.? or lv!L/11. It is usually class ilicd as a sub-type of Lynch Syndrome instead 
of a separate disease. 'Turcot Syndrome' \vas lirst described by Turcot eta/. in 1959 and 
is not really a syndrome, but the combination of polyposis or colon cancer and brain 
tumour. This combination can occur due to mutations in /1 PC, .\4/J II or i\!{Sf n. or 
hom<li'ygous or compound hctero1ygnus mutations in P.\IS:l (DeVos et of .. 2004). 
-5-
·Turcot Syndrorne' i:-. generally clwr:tC!erisL·d h) a milder po lypo~is than F P. but\\ ith 
cancer of the centralner' ous systL'tn in addition to CRC. This can occur in one person in 
an F,\P or Lynch Syndrome l'amily. 
nother genetic mal ignancy syndrome that can be caused by MMR mutations is 
eurotlbmmatosis Type I (NF I). 'F I is an autosomal dominant condition usual) 
caused by inheriting a mutation in the . F l gene and is general ly characterised by 
multiple calc au Ia it spots and fibromatous tumours of the skin, with a wide range of 
other manifestations (OM IM 162200). It has been shown that homozygous MLHI 
mutations (Riccia rdone c>t a/., 1999; Wang eta! .. 1999) and homozygou. /viS!/] 
mutations (Whiteside eta/., 2002) can both cause de novo cases or F I in children. One 
study has ·hown that patients who arc MMR defi~.:ient due to homozygous MLf/1 
mutations have somatic mutations the in NFI gene causing an NFI-Iike phenotype 
(Wang eta/., 2003). 
I . I. 3 Historl' o( L l'llch SJ'ndrome: 
In 19 13, Warth in published a paper on several families he described as ''cancer 
fratern ities" which he had followed . incc 1895. In his paper, he des~.:ribed a Cancer 
Family "G" which had a high incidence of carcinoma of the colon, endometrium and 
stomach (Warth in eta/ .. 1913). Warth in revisited "Family G" in 1925 and gave an update 
on the cancer incidence in an expanded lnmi ly tree. I Ic stated that the lami lial 
su:-.ceptib ility for gastro-i ntestinal cancer in rnalcs am.! the ''generative organs" in females 
" as inherited in a rcccssi\'c partern (Warth in t'l a! .. 19~5). In 1936 "Family G" was 
-6-
ill\~.:stigat~.:d again by llaus~.:r and Wclkr and th~.:y published an ~.:xt~.:rHkd l~unil y tr-c~.:. 
They conlinneJ the presence ol'the familial susceptibility in the liunily. and the primar 
incidence or gastro-intestinal and endometrial cancer. They also stated that no conclusion 
concerning the inheritance pattern could be made at that time (llauser er of.. 1936). 
In 1966 Lyncher a!. published a paper entitled "llcreditary Factors in Cancer: 
Study oi'Two Large Midwestern Kindreds". The identified two families in the United 
States that suffered from what Lynch described as a "cancer family syndrome" that had a 
similar phenotype to Warthin's Family G. Lynch was unsure at the time what the specific 
cause might be, but postulated that there might be an autosomal dominant inheritance. In 
1967, Lynch eta!. described 6 more ''cancer t~1milies" including Warthin 's Family G. In 
this paper, the speci fie phenotype of Lynch Syndrome was becoming clearer. For the first 
time, Lynch commented on how colon cancer was the primary cancer seen in the 
syndrome but also described the early age of onset and the occurrence of specific 
extracolonic tumours. Lyncher a!. examined "Family G" again in detail in 1970. Cancer 
of the colon. endometrium, and stomach were reported to predominate, but there was 
also increased incidence of leukemia and of sarcomas, which were not present in Lynch's 
''cancer family syndroml:". Lynch suggested that modifier genes might innucncc 
dcvdopment of additional cancers in the syndrome (Lynch era!., 1970). 
In 2000. a subject from "Family G" was screened for mutations in mismatch 
repair gene: . An ,'v!S/1:! mutation, c.646-3T>G, was found that alters the splice acceptor 
site for exon 4. This change results in a protein that has g amino acids inserted between 
codons 215 and 216 making it functionall y inacti\l~ (Yan er ul .. 2000). ''Family G" \\'as 
-7-
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rcimcstigateJ in 2005 and preJic ti\·e mutation testing \vas performed !'or all willing 
members or Warthin 's "Cancer Family". a little 0\ er II 0 years after Warth in lirst 
ill\ estigatcd this l'amily (Douglas L'1 ({/ .. 2005). 
1. 1.4 Lrnc!J Srndm111e Risk Critaiu : 
1.1 .-1.1 .·lmstacla111 Criteria: 
In 19t.>O. the International Collaborative Group on I I PCC ( ICG-H PCC) met in 
Amsterdam. I lolland to develop criteria for classifying whether a 11tmily was at high risk 
for Lynch S yndroml:. Due to the I ocation of the meeting, these critcri a become 
popularised as the "Am tcrdam Criteria" (ACI). The requirements of the ACI arc as 
follows: three family members (one of whom is a lir t-degrec relative of the othi.:r two) 
in two or more successive generations must have had colorectal cancer and at lea tone 
case of colorcctal cancer should be diagnosed under the age of 50. ln addition to this, the 
diagnosis of Familial Adenomatous Polyposis or Attenuated FAP must be excluded 
(Vasen eta/., 1990). In 1990, the genes re ponsible for Lynch Syndrome were unknown, 
so these criteria were primari ly used for selecting t~tmilies for linkage analysis. They 
were specific, but not sensitive and excluded a number of families with Lynch Syndrome 
that had a high incidence of cxtracolonic tumour . In 1999, the ICG-HNPCC met again in 
I Iolland to create a modi tied ACI, which they dubbed the Amsterdam Criteria II or 
ACII. They modilicd the ACI keeping the same basic requirements as before, but now 
included cxtracolonic tumours (endometrium, stomach, small bowel. renal pclvi . . ovary, 
brain and hcpato-biliary) in the Lynch Syndrome spectrum instead of on ly CRC. The new 
criteria arc used to pre-screen l~1 milies for genomic sequencing ofMMR genes which is 
-X-
an cxpcnsi \·e and ti me consum ing process (Vasen el (1/., 1999). 
1. 1. -1.:! Be!hesdu Crileriu : 
The Cl and AC II criteria arc useful f(Jr c lassifying fami lies. but addit ional 
gu idelines exist for selection ofindi'viduals \\'ho may be at risk for Lynch Syndrome. 
These arc termed the ''Bethesda Cri teria"' and were developed in 1997 (Rodriguez-Bigas 
eta/., 1997) and modified to the ''Revist:d Betht:sda Cri teria'' in 2004 (Umar e1 a/., 2004). 
Persons who mt:t:t the Bethesda Criteria ( BC) arc recommended to be screened for 
cia. sica! molecular features of Lynch Syndrome such as microsatellite instability and 
deficiency ofMMR proteins in their tumour cells prior to genomic mutation testing. 
sing the BC allows for screening to become more efficient in two ways. First, only 
selected cancer patients that meet BC would be pre-screened for characteristics of Lynch 
Syndrome, thus saving time and money through not testing non-MMR deficient cases. 
Secondly, only those persons who both meet the BC and show features of Lynch 
Syndrome would be tested by the more expensive mutation screening, giving a second 
leve l of control. The complete Bethesda and Revised Bethe. da guidelines arc listed in 
Appendix I. 
/ . /.4.3 Af:e and Cancer l•vfodified Amsterdam Criteria: 
The AC II have been modified following study of the ewfoundland population to 
identify heri table forms of canct:r with a later age of onset and more va riable cxtracolonic 
tumours. In these new criteria, the age of cancer is modified to under 60. Also. the range 
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or cancers lis ted in AC II ha\ e been expanded tn incl ude the Rev ised Bethesda Criteria 
cancers. These ne\v criteria :~re rcferTed to as Age and Cancer Modi li ed Amsterdam 
Criteria (ACM C) (Wonds eta/ .. 2005). Since the IMR genes have been identilied. 
these criteria arc useful for selec tion or patients for mutation testing, as well as to identify 
linkage analysis l'or new genes that may be responsible ror cancer syndromes outside of 
the mismatch repair pathway. 
1.1.5 Mismatch Repair Patlrwar: 
Mutations in the mismatch repair (MM R) genes arc responsible for Lynch 
Syndrome. Mutations in these genes leave an individual with only one functional copy of 
a particular M M R gene, thus with no second copy if it is somatically mutation, making 
DNA mismatch repair vulnerable. MMR is responsible for the post-replicative 
identification and repair of mismatched bases or sma ll in crtions/dcletions. While a 
single copy of a MMR gene is sufficient to maintain nonnal cellular DNA repair, 
individuals with a sole functional copy leave a cell susceptible to accumulating mutations 
if this is inactivated. These mutation arc not specific, but can affect genes that either 
inhibit cell proliferation in their nmmal capacity (tumour suppressing), or genes that can 
induce ce llular proliferation (tumour inducing) thus increasing a person's risk or 
developing cancer. To date. there arc four MMR genes that Lynch Syndrome causing 
mutations: .\ILl-fl. ,\;/SII:J . . \JSI/6. and PMSJ. ,\IU II and MSHJ combined account for 
approximately R0° ~) o r kno\\'n Lynch Syndrome mutati ons (Woods el a/., 2007). 
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/ . / . () ,\lisnwtch Repair Genes : 
The .II. //] gene is located on chromosome 2p2::!-21 and was the lirst gene known 
to cause Lynch Syndrome when mutated (Fishel. c:t a!. 1993, Leach, L'l a!. 1993, 
Peltomaki , eta!. 1993). The ,\/SIC gene spans 16 exons which produces a 3, 1-+5 base 
transcript that encodes a 934 amino acid protein. MS/16 was first reported as a unknown 
MM R protein in 1992 by Hughes and Jiracny and later named GTBP or G, T mismatch 
Binding Protein (Palombo eta!. , 1995). It was mapped to 2pl6 and also causes Lynch 
Syndrome when mutated (Papadopoulos et a!., 1995). The lv!SH6 gene spans I 0 exons 
which produces a 4,255 base transcript that encodes a 1360 amino acid protein. The 
protein product of MSfl'l. form s a heterodimer with the protein product of MSJ-16 or 
MSHJ to form the MUTScx (Drummond eta! .. 1994) or MUTSP (Palombo eta!.. 1996) 
complexes respectively. The dimcrization domains ofMSH2 arc in the middle of the 
protein and at the C-tcrminus (Bandipalliam, 2007). MUTScx scans D A for mismatched 
bases as well a small insertions or deletions while MUTSP scans forD A loops caused 
by insertions or deletions (Palombo, eta! .. 1996). When these complexes detect a 
mismatch, insertion or deletion, they recruit additional proteins such as MLI II , PMS2 
and EXO I to first exci c and then repair the error. Variations in the EXOI gene do not 
appear to cause Lynch Syndrome (Thompson eta!.. 2004). 
The /vfL!-1 I gene is located on chromosome 3p2 1-23 and was the second gene 
di sclwerecl to cause Lynch Syndrome when mutated (Bronner eta!. 1994; Papadopoulo. 
eta/. 19lJ.f). The JILl II gene spans 19 exons that produces a 2.524 base transcript that 
encodes a 756 amino acid protein. The MLI II protein form. a hctcrodirncr \Vith the 
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prntein product oi'P.\IS:! to l'orm the 1\IUTLct compk:x . The PMS2 binding domain is 
located at the C-terminus of the 1\1 Llll protein ( Bandipalliam, ::W07). The P,\IS:! gene is 
located m1 chromosome 7p22 and is al so responsible rnr Lynch Syndrome when mutated 
( icolaides ef al., 1995). It spans 15 cxons which produce a 2,802 base transcript 
encoding an H62 amino acid protein. The MLI-11 protein also t(mns a heterodimer with 
the MLI 13 protein to form MUTLo (Cannavo l.'f al., 2005). Some variants in the .'vf/J!J 
gene seem to be associated with a weak l~tmilial cancer risk but not Lynch Syndrome 
(Liu er al., 2003). Either the MUTLct or MUTLo complex is responsible for recognising 
MUTSct/MUTSP bound to mismatches. MUTLct/MUTLo then recruits the EXO I protein 
to excise the error and allow D A polymerase to Iii I in the gap. 
/./. 7 Molecular Characteristics o[Lvnch Spndrome: 
I . I . 7. I Microsatellite lnstabilill': 
Microsatcllite Instability (MSI) is a hallmark feature of Lynch Syndrome. MSI 
involves either the shortening or lengthening of short tandem repeats of DNA, called 
microsatellites. These microsatellites which can be either mononucleotide repeat , di-, 
tri-, tetra-, pcnta- etc. When the MMR pathway is compromised, these repetitive clements 
accumulate insertions or deletions that would normally be repaired. Whether these 
repeats arc microsatellite stable (MSS). or display instability (MSI) can be determined 
via amplification of the repeat in both normal and tumour DNA and comparing the 
rclati\ e sizes. Specific microsatellites can be amplified and examined to detect expansion 
or contraction. This detects whether or not the MMR patlnvay is functional. This is a 
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simple and enicient system to e'<:unine the ~I~IR pathway. but gives no indication of 
\\ hiL·h gene mi!!.ht he impaired nr how. Whik MSI is associated \\' ith Lynch Syndrome it 
can also be seen in sporadic colorectal cancer. !\ proportion(~ 15%) or older patients\\ ith 
sporadic CRC \\ill displa MSI in tunwur DNA. This MSI is commonly due to the 
epigenetic inaeti\ation of the .\IU/1 gene through hypermethylation ofthe promoter 
(Cunningham eta/ .. 199X) or may rarely occur because of two somatic mutations ofthe 
,'v/ L/11. MS/ 11, AIS/16, or PAIS] genes. llypermcthylation of the lv/L/11 promoter is a 
cause or transcriptional silencing and the incidence or methylation increases with age 
(Cunningham eta/., 1998). A recent study has also shown that MSHl can be inacti ated 
by promoter hypermethylation. and this change can be inherited (Chan eta/. , 2007). 
1. 1. 1. 2 lmmunolrisfoclremistrv: 
Detecting the protein products or 1MR genes is another u eful way to as ess 
MMR pathway function . Immunohi tochcmistry (IHC) is used to tain cell for the 
protein products of specific genes. This is done by staining section of'tumour tissue with 
monoc lonal antibodies directed against a particu lar protein. For Lynch Syndrome these 
proteins arc M U II, MSH2, MSH6 and PMS2. Negative IHC means that there was no 
protein product detected in the tumour tissue. This means the gene i. inactivated or not 
producing the correct protein in the tumour. either by germline and!or somatic mutation 
or epigentic silencing. The absence or a MMR protein in tumour ti sues means that this 
gene has been inactivated. though the exact mechanism is not clear rrom IIIC alone . 
IIIC and \tiS I status arc key molecular markers !'or screening CRC litmilics ror 
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LS. These tests can be used as independent risk criteria. but arc more uscl'ul in parallel. 
They pro,·ide inl'ormation about the underlying genetic cause ora tumour. MSI status 
provides information on the status of the MMR pathway. while IIIC provides inl'ormation 
as to which gene or genes arc inactivat~..:d. gi ving direction to mutational studies. 
In format ion li·om both o I' these key LS mark~..:rs was used substantially as screening 
criteria in thesis' work . 
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1.2 Objectives: 
The objectives ofthis thesis' \vork \\ ere twofold. First. to determine the 
proportion ofCRC in the ewi(Hmdl:tnd population resulting from gennline mutations 
ofthe primi.lt) MMR genes: .\!Sit:! and .\/1./// . Ciermline mutations in these t\.\'O genes 
\vould indicate the prevalence of Lynch Syndrome in ewfoundland. By using a 
ewfoundland-based CRC registry, a population based approach can b~: used that would 
idetllil'y liunilies in the general population outside of those known high risk l~1milics. This 
will allow a better indication of the incidence of LS in the population. The second 
objective was to cata logue and compile all ariants in the MMR genes MS!I2, MLHI, 
and .~fSHn that have been published in the literature. There were no comprehensive and 
current databases of variants of LS at the time of this undertaking. l11is database was 
developed to provide an inva luable resource for this thesis' work as well as for other 
researcher · of Lynch Syndrome. 
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Chapter 2 
2.0 Population Based Study of Lynch Syndrome in 
Newfoundland 
2.llntroduction: 
Newfoundland and Labrador has the highest age-standardised rate of colorcctal 
cancer of all Canadian provinces tor males (82/ 1 00,000) and second highest tor females 
(51 / 1 00,000). This incidence is reported as an underestimate for Newfoundland and 
Labrador due to undcrcounting (Cancer Canada). Several Lynch Syndrome MMR 
mutations have been previously detected in the Newfoundland population. These include 
two large deletions in the MSf/2 gene, one being a deletion of Exon 8 
(c.l277-? _ I 386+?del. p.Lys427 _ Gln462>GiyfsX4) (Woods eta/., 2005), and the second 
a deletion ofcxons 4 to 16 (c.646-?_2802+?dcl) (Woods eta/., 2005). There is also a 
mutation which disrupts the intron 5 splice acceptor site of MSH:!. c.942+3A>T (a .k.a. 
the "Family C mutation"). leading to incorrect splicing out of cxon 5 via post-
transcriptional moditication (p.Va l265_Gln3 14del) (Greener a/., 2002). A promoter 
mutation in ,HLH ! . c.-42C>T, leading to an approximate JJ%, efficiency in gene 
transcription has also been reported in the ewtoundland population (Green eta/., 2003). 
In addition there arc many families that di play the clinical characteristic of Lynch 
Syndrome in which MMR mutations ha\e not been to und, giving ri se to the possibility or 
nmel hereditary cancer syndrome genes outside of the MMR pathway. 
The island or I ewfoundland presents an ideal environment tor the study or 
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genetic disL'ascs. The current population ol' I t:\·\ 1(1undland is approximately 505.000 
(\\ \\ \\ . .; tats.;;m .nl.ca). The island was populated by 20.000-JO.OOO settlers mainly li·om 
South-West England and South-East Ireland between the years of 17o0-l H20 (Manion .1.1 , 
1977). This makes the genetic stn.1ct ure n r the population very homogenous. Settlers 
came to Ncwl'oundland primarily for the occupation ol'lishing. <mel because of this. 
rounded many small "outport" communities all along the island's coast where travel was 
limited until the 20111 century. Due to the small number or settlers, carriers ofMMR 
mutations who settled in Newfoundland have enriched the Newfoundland population 
with Lynch Syndrome via a founder effect. A founder effect is when a small number of 
initial settlers with a decreased amount of genetic variation from the original population 
form a new population, leading to an enrichment of particular alleles in the new 
population. This limited number of settlers in ewfoundland has also created a limited 
pool of modifier genes acting on LS as well. This homogenous population, enriched in 
mutations, may allow study of how mutations behave with spccitic modifiers, and how 
these may act to alter phenotype. 
___ It has been proposed that the high colorcctal cancer incidence in Newfoundland is 
caused by a high frequency of Lynch Syndrome due to a population enriched in founder 
MMR gene mutations. This hypothesis was tested by examining cancer patients who 
were diagnosed with colorcctal cancer in Newfoundland for the five year period of 1999-
2003 and determining MMR mutation status for those fulfilling high risk criteria for 
Lynch Syndrome. All CRC patients in Newfoundland during this period were eligible to 
be entered into the Newfoundland Colorectal Cancer Registry ( FCCR). The NFCCR 
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was thcn uscd to identify (tktails rc,·iL'\\Cd in the :V1aterials and Methods section) those 
subjects \\'ho have characteristics ofl.ynch Syndrome, ami slwuld be tcst-:J !'or MM R 
mutations. ldcntilication of positi\'c M IR mutation status, indicating Lynch " yndromc, 
will allow t<.1r enhanced clinical care in patients ti.nmJ to be cmTiers, as well as 
potcntially a!Tccted family members. 
With a known t~1mily mutation. it is casier to screen l ~1mily members through 
genetic testing. It is no longer required to pert<.mn expensive exon by exon scqueneing of 
multiple genes searching lor an unknown mutation, or to otTer expensive clinical 
screening to all family members. When subjects arc found to be ca rriers, specific and 
intensified preventative clinical screening at younger ages than the genera l population 
should allow for earlier detection and treatment of carriers. Family members who were 
previously ''at-risk", but who receive negati ve genetic test results, will be given piece of 
mind, as well as ceasing any unnece. sary screening other than the general population 
recommendations. 
Another possible benefit of this project is the exclusion of high ri k criteria 
families from being Lynch Syndrome families. If it is known that a fa mily i · not a CaJTier 
ufan MMR gene mutation and st ill mel!ts ACI risk criteria, these families would then be 
idea l candidates in screening for novel genes responsible tor Familial Colorcctal Cancer 
Type X. 
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2.2 :\tlatcrials and Methods: 
] . ] . / Suhjects: 
Research subjects inclu(kd in the Ne'' roundland Colorcctal Cancer Registry 
FCCR) \\'ere those diagnosed under the age ol· 75 with primary CRC in the province of 
1evvroundland and Labrador during the period or 1999-2003. Subjects ali eat time of 
contact gave inronm:d consent, and those previously deceased were consented by proxy. 
Subjects were asked to provide a blood sample from which genomic DNA was extracted. 
Also, D A was extracted from paraffin-embedded tissue samples of patients' colon 
tumour and normal mucosa for MSl testing. IHC staining of tumour tis uc was performed 
to determine expression of MLH I, MSJ-12 and MSl-16 proteins. Promoter 
hypermethylation causing epigenetic sikncing of MLHJ was also determined in selected 
cases. Family histories were obtained and families or subjects were classified by the 
Amsterdam Criteria or Revised Bethesda Criteria. Subjects who had blood D A 
available before June 30'", 2005, and met screening criteria, were all tested for mutations 
in MLH I and MSf/2. 
?.2.2 Screening Criteria : 
A hierarchal molecular testing scheme was employed to triage subjects for 
mutation testing (Sec Figures 2.2 and 2.3 in the results section). In bricl: testing for 
genomic rearrangements via Multiplex Ligation-dependant Probe Amplitication (MLPA), 
a relativcly inexpensive and quick test. was performed lirst. This was performed on 
subjects'' ho met famil y criteria or either CL ACII or the highest category of Bethesda: 
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(lnll:rm~diate I (I NT I) Appendix I) and had tumours \\'hich ,,·en: MSI high (MS I in at 
least 2 of 5 microsatellit~ markers t~s t ~d). or IIIC ddicient for MLIII. MSII2 and. or 
MSII6 . Samples \Vhich did not sho\\' largL' genomic r~arrangement s were then tested 
according to th~ following criteria: subjects whose tumours were IIIC dcticient for 
MSII2. or were ACI nr ACII, were all tested for a common splice variant in 
Newfoundland, c.942+ JA>T (rell:rred to as the "Family C" mutation). via sequencing. 
This is the most common Lynch Syndrome mutation in the published literature and a 
founder mutation in Newfoundland (Froggatt eta/. , 1999; Woods eta/., 2007). It alte rs 
the splice acceptor site for cxon 5 of J\t!SH2 resulting in the in- ti"c1me deletion of exon 5 
(p.Yal265_Gln314del) in the MSH2 protein. Samples that were negative via MLPA and 
"Family C" test ing underwent further testing. Samples that were IHC deficient for either 
MSH2 or MLHI, or fultllled the ACI or ACII criteria were sequenced exon by exon in 
either MLH I or MSH2 from polymerase chain reaction (PCR) products (Mullis et 
a/., 1986). These two gene. account for greater than 90% of all variants in LS (Woods et 
a/.. 2007). Subjects whose tumours were deficient in MLH I by IHC were only sequenced 
if there was no hypermethylation of the MLH I promoters. 
J. 2.3 Alultiplex Ligation Dependent Pro he A mplificarion: 
M LPA is a relative ly new procedure developed by Microbiology Research Centre 
llolland (M RC-IIolland) which detect · genomic deletions or duplications. In brief. this 
system \vorks by having t\\ o probes for each genomic cxon, which arc ligated together 
when annea led to genomic DNA. The ligated probes arc then amplified by fluorescent 
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dy~-lab~lku prim~rs. Comparison o!'amounts ol' ligali.:d and amplilicd probe in t~st 
sampks. n:lativ~ to normal controls (intact g~nomic indi viduals with no d~ktions or 
duplications, th~rdor~ t\\ o copies of each exon). makes it possible to detect deletions or 
duplicatinns ofentin: ~xons . pon probe amplilication of an exon there will be 
approximali.:ly 50° o ofamplilied product (ligated probe) per deletion, or approximately 
150°1n of the ampliticd product per exon per duplication as compared to a control with 
two copies of each gene. 
___ An M LPA kit was available for all exons or MLH I and MSH:l. Exonic 
rearrangements in MSH:l and MLH I arc fairly common (Woods eta/. , 2007). They arc 
less common in MS!I6 and there arc no data concerning large deletions/duplications in 
PMS1, MU-/3, and MSf/3. Due to the low co t of the test ($15 per patient), as well as the 
case and speed of the procedure, MLPA was used as the initial mutation screening test. 
Samples were always tested under the same reaction conditions with at least five 
controls. All samples and control fi·om each reaction were analysed via the Beckman 
CEQ-~WOO Genetic Analysis System (Beckman Coulter Canada, Inc., 6755 Mississauga 
Road, Suite 600, Mississauga, Ontario, L5N 7Y2). Any samples that showed a deletion or 
duplication ia MLPA were repeated for confirmation. 
::. 1.4 MLPA R eaction Conditions: 
Samples to be tested by M LPA (Figure 2. 1) \vere amplified according to the 
manufactur~r·s protocol. available from " "" . m lp~~. .. - ~~, n . In a Eppenclorf Mastcrcyclcr 
Gradient th~rrnocyc lcr (fppcndorf. 6670 Campobello Road Mississauga, Ontario, L5N 
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a. PCR primer sequence Y 
'--
b. 
c. 
d. 
Hybridisalion 
sequence 
5'-.__) 
3' Target A 5' 
s·~ 
3' Target A 5' 
y X 
5' 3' 
_j PCR primer sequence X Stuff r 
sequanoe ach M13 derived probe 
Hybridisalion oligonuclieotide has a 
sequence d ifferent stuffer equence . 
..J;robe added to test DNA and allowed to hybridise 
J 5 y 
3' Target B 5' 
..J,U gati on reacti on 
sY 
3' Target B 5' 
Tho two parts or each 
probe hybrldlse to 
adjacent target 
sequences 
The two parts of 
hybridised probes are 
ligated by a thermostable 
ligase. 
..J;CR amplifrcation using a single primer pair 
Y X The amplification product of 
-
5
-. - - ---- each probe has a unique 
3' length (130-480 bp). 
Fi2ure 2.1: MLPA Probe Hybridisation and Li2ation: Graphical representation of 
different size MLPA probes hybridising with DNA and the ligation reaction generating 
the amplification product where target A is one exon, and target B is a different exon. 
(http://lccdsdna. in fo/HUG0/2004/Lab _ Notcs/1 magc33 .gi J). 
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2L~). I OOn~ or genomic DN,\ ''as diluted \\'ith 5 pi orTE burfcr. denatured at 9R''C lt) r 5 
minutes. and then cookd to 25''C. At 25''C. 1.5 pi or SALSA Probe mix and MLPA 
buller'' ere added. and mixed' igorously by ripctting at kast I 0 times. Sampks were 
then incubated at 90''C for I minu te, and the probes were hybriclised at 60''C lo r I o hours. 
For the ligation reaction, the temperature \Vas reduced to 54''C and 32 ~-tl or·'Ligasc-65" 
mix was added and mixed by pipetting, incubated at 54"C 15 minutes ror ligation, and 
then heated I(H· 5 minutes at 9W'C to inactivate the ligase. "Ligase-65" mix was made 
fresh within an hour of use, stored on icc and consisted of 3 ~d of''Ligase-65" buffer A, 3 
111 of ligase buffer B, 25111 ofdeioniscd water and I 111 ofLigase-65 mixed by pipetting. 
Following ligation , " PCR Protocol Two"(\\" '"·mlp;1.co111) was followed to amplify the 
ligated probes with fluorescently labelled primers. For "PCR Protocol Two'', 4 111 of I OX 
SALSA PCR buffer, 20 ~-tl deionised water, and 10111 ofMLPA ligation reaction were 
mixed, and then put into the thermocycler and held at 60''C. While at 60°C, I 0 111 
Polymerase mix was added, and the PCR conditions were as follows: 30 cycles of 30 
seconds at 95"C, 30 seconds at 60"C, 60 seconds at 72"C, followed by a 20 minute 
incubation at 72"C. Polymerase mix was made fresh within an hour before usc, stored on 
icc and consisted of2 ~d ofSALSA PCR-Primcrs, 2)11 of SALSA Enzyme Dilution 
buffer, 5.5 111 of de ionised water, and 0.5 ~LI or SALSA Polymerase. 
].].5 /v!LPA Fragment .. tnalrsis: 
Aller completion of the PCR reaction, 0.7 111 of the PCR reaction. 0.5 pi of the 
Beckman D 1-labc lkd 60-600bp molecular weight marker and 40 pI of Beckman Sample 
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Lnading Solution (SLS) \\'ere mi xed and loaded into the CEQ-XOOO system for fragment 
anal ys is . Settings ror the rragment analys is were as rollows: capillary temperature or 
50"C. denaturation of90 "C ror 90 seconds. injection time of1 .0 KV for 60 seconds and 
runtime or60 minutes at -Ul KV. 
Each test run was analysed by the CFQ-8000 fragment analysis software 
according to the rollowing settings: peaks 3% wen.: included; size standard-600 
(Beckman nr. 608095); and a slopl! threshold of I . Thl!sc sett ings included all of the 
cotTl!ct peaks for dosage analysis, but also included size standard peaks, as w~.:ll as 
background and shoulder peaks. A filter was applied to the analysed data whereby dyes 
Dl, D2 and DJ (which were not probe specific) were excluded, peak areas less than 5000 
Relative Fluorescence Units (RFU) were excluded, and peak sizes lcs than 125t1l were 
excluded. This filter eliminates ambiguous peaks, but each electropherogram was sti ll 
manually reviewed to include some probe peaks less than 5000RFU, and to eliminate 
noi s~.: peaks greater than 5000RFU due to variations in peak size. 
2.2.6 Dosage Analvsis: 
Data including peak s iz~.: and height were then copied in to an Excel spread shed 
devl!lop~.:d by recommendations fi·om th~.: ' ' '' '' .mlpa.com website. The websi te provided 
a template. which vvas then modifkd to be applicable for the II PCC-I(ML/1/ and 
,t /SI J:l) kit. 
Firstly. ror each of the normal controls and test samples the peak area for each 
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probe was added to gi\'e the total area . Each probe area was di vided by the total to gi\ e 
the relatiw !'ract ion for each probe of the total area. For normal controls. this relati\e 
li·actinn \\'aS then averaged for each probe over a lithe normal controls. 
Ne:xt. each relative probe area !'or both normals and test samples was divided by 
the average relative rraction f(w the normal controls. The average of each relative fraction 
was then taken for each test and control sample. Finally. each relative fraction was 
divided by the average relative fraction to give the final result. Output was generated in 
an excel spreadsheet colour coordinated by dosage. 
The final output of analysis was colour-coded for case of identification: yellow 
for normal relative dosage. if within 20% of 1.00 (2:0.80-.:::1.20); dosages within 20-30% 
of 1.00 were intermediate results and were coded pink if less than 1.00 (2:0.70-<0.80), 
and light blue if 20-30% greater than 1.00 (> 1.20-< 1.30). Output for relative dosage of 
<70% or 2: 130% is indicative of either a deletion or a duplication relative to the control, 
and displayed as red ifS0.70 and dark blue if _1.30. MLPA data for each gene was then 
recorded in a spreadsheet labelled by D A number. 
2.2.7 Direct Sequencing for Mutation Detection: 
7.1 .7. 1 PCR D Ni1 Amplification: 
Polymera. e chain reaction (PCR) (Mullis et u/ .. 1986) was used to amplify all 
cxons and flanking intronic sequences or MMR genes MLH I and .\4SHJ. PCR products 
\\'ere then puriticd for genomic sequencing in a Beckman CEQ 8000 Genetic Analysis 
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System Primers were ordered fro111 Operon, a di\ ision of(.)iagcn (QIA<iE Inc .. 2XOO 
rgcntia Road, nit 7, Mississauga, Ontario, L5 XL2). PCR t\:actions were pcrlimncd 
in a 8iomctra T I tlH:rmm.:yclcr (£3ion1l:tra G111bll I. L., Rudolf'.-Wi sseii-Stral.k JO, 37079 
Ciocttingen. Cicrmany). 
The reaction conditions I(H· MU II and ,\/S/1:3 pri111crs were as follows : 95"C I(H 2 
minutes. J5 cycles of denaturation at 95''(' for JO seconds, annealing at 55"C for JO 
seconds and elongation at 72" lor I minute. Then a tina! elongation at 72"C lor 5 
minutes. 
Concentrations used for the PCR reactions were optimized for the PlatiniumTaq 
polymerase kit from Invitrogen (Invitrogen Canada Inc. , 2270 Industrial St., Burlington, 
Ontario, L 7P I A I). Final concentrations per 25~-LL reactions were as follows : I X Buffer 
solution (I OX stock provided by the manufacturer, with 20mM MgCI2), 0.611M of each 
primer, 0.2mM of each deoxynuc leotide triphosphate (dNTPs) and 0.75 units ofTaq 
polymerase. Reaction products were stored at 4"C until they were analysed via 
electrophoresis on a 2% agarose gel stained with cthidium bromide visualised under V 
light for PCR product verification. Primer sequences arc summarized Appendix 2. 
1.1.7.1 PCR Product Purification : 
To l~lC ilitatc ckan up for sequencing reactions, the PCR reactions were purified 
by ExoNuclease I (Exol) and Shrimp Alkaline Phosphatase (SAP) to digest excess 
primer and dephosphorylatc surplus free nuclcotidcs respectively. In the thermocyc lcr. 
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7~L of PCR product was incuhatcu with 7 . 5~L lkioniscu \\'ater. 0 . 5~L I L' ~L of SAP 
and 0.5~L of IOU ~L Exol. Reaction conditions \\'Crc 30 minutes at 37"C follo\\'ed by a 
I 0 minute inactivation step at XO''C. 
1.1.7. 3 Secfllencim; Reaction: 
Each amplicon was sequenced in both the reverse and forward directions. 
Sequencing reactions were set up using I /4 the recommended sequencing reagents to 
conserve reagents while still giving reliable results. Reactions were made to the following 
specifications: Sequencing buffer, 0.325pMol ofprimcr, I~L of purified PCR product, 
and I ~L of DTCS Quick Start Mix with final volume of 20~L. Thermocyclcr conditions 
were as l"ollows: 30 cycles of96"C for 20 seconds, 50"C for 20 seconds, and 60"C for 4 
minutes. The sequencing reaction was stopped by the addition of 5~L of freshly prepared 
stop solution. The stop solution had a final concentration of 1.5M Sodium Acetate. 
50mM Sodium EDT A at pH 8.0 and 4~g of glycogen and was prepared less than an hour 
before usc. 
:!. 7.7. 4 Seauencing Reaction Purification: 
Arter the addition of stop solution, the en tin: volume of the reaction was mixed 
with 60~1 ol"95"o ethanol that had been stored at -20''C. inverted 5 times and mixed by 
vortex before being centrifuged at -l"C and JOOOg for 40 minutes. Following this spin, 
sampk plates \\'ere inverted, and ethanol decantcu. Sampks were then washed by the 
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addition of 2001-J.I of 7()<' o ethanol that had been stored at -20"C and spun at 4''C and 
.1000g for 5 minutes . This \\'ash step \\'as repeated !\vice. Following the second washing. 
th~ sarnpk plate was kfl inverted and centrifuged again at 300rpm to r~mo\'e any ~xcess 
ethanol. amplcs \\ere len to dry in a desiccator for approximately 15 minutes. Samples 
were then resuspended in 301-J.I of SLS, and co\'erecl in mineral oil for analysis in th~ 
Beckman CEQ-8000 Genetic Analysis System. 
2. 2. 7. 5 Sequence A nalvsis: 
The run conditions for analysis of sequence fi·agmcnts was the LFR-b default 
program in the CEQ-8000 software. This program consisted of capillary temperature of 
57"C, denaturation of 90"C for 120 seconds, injection at 2.0 K V for 15 seconds and 
runtime of60 minutes at 6.0 KY. Sequence data were exported and analysed on a remote 
workstation. The analysis settings were modified from the default as follows: PCR 
product option was selected, heterozygote detection was enabled, and a reference 
sequence was included in the analysis. 
Forward and reverse sequences for each ~xon, as well as for the reference 
sequence, were reviewed and manually compiled using the Beckman CEQ-~WOO Genetic 
Analysis System sonware. Sequence data were then recorded in a spreadsheet coded by 
DNA number. 
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2.3 Results: 
ThL·re \\'CIT 779 patients in the NFCCR as or June 30th' 2005 (end date or this 
thesis' work) and 56X (73°·n) had genomic D A avai lable from bloou extraction. Of 
these, 536 (9...J.0 n) where intact forM Llll, MS112 and M. 116 proteins by II IC, and 32 
(6° ~,) showed a deficiency of at kast one MMR protein. This can be broken down to 16 
IIIC delicient for MLIII (50tY;, or all Ill C), 6 IIIC delicient !'or MSII2 ( 19%) and 15 II IC 
delicient lor MSH6 (47%). The numbers add up to greater than 100% due to the f~tct that 
many of the samples dclicient !'or MSII6 protein were deficient for one of the other 
MM R proteins as well. Of the 15 IIIC deficient for MSH6, only I 0 of these were 
deficient for MSH6 alone. Three samples were deficient additionally for MSH2 and two 
deficient additionally for MLH I. The complete breakdown of samples can be seen in 
Figure 2.3 . 
2.3. 1 MSH2: 
In total, I 15 subjects (Figure 2.2) who had available genomic DNA met criteria 
(ACI/ACII/INTI or IHC ncgati e for MLH I or MSI 12 or were MSI high) for testing via 
MLPA . None of these samples showed any duplications or deletions in :'v!SH1 (Figure 
2.2). 
There were 22 subjects" ho met criteria (ACL'ACI I or II IC negative for MSII2) 
lor testing for the common Nc" ·rounuland .. Family C' mutation. Of these subjects, 4 
\\ere pn~itive l(lr the mutation (Figure 2.2 ). 
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Th~rc were 14 subj~cts \\'hu m~t crikria ( ,\CI. t\Cll or IIIC n~gati\'~ for MSII2) 
l{)r compkt~ s~qu~ncing of .1/S/ C . Ek,·~n polymorph isms whcr~ found. but no 
pathogenic mutations. A list ofpolymorphisms and ··Family C .. mutations found is 
summarised in Table 2.1. 
:?.3 . .? iv!Lf/1: 
In total. 115 subjects (Figure 2.2) who had available genomic DNA met criteria 
(ACIIAC !/ INTI or IHC negative for MLH I or MSl-12 or were MSI high) for testing via 
M LPA None of these samples showed any duplications or deletions in MLH I (Figure 
2.2). 
There were 15 subjects who met criteria (ACIIACII or THC negative for ML!-11) 
for complete sequencing of MLH I. Seven polymorph isms where found, but no 
pathogenic mutations. A list of polymorphism: found is summarised in Table 2.2. 
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Fi2ure 2.2: Mutation Analysis Flow Chart: Flow chart illustrating samples tested via 
MLPA and subsequent testing and results. 
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Table 2.1: l\lutations and Polymorphisms found in MSI/2 
Ex on/ Blood Base Change 
In Iron D A ID 
I ntron 5 RD-2 17 c.942 t-3 A>T 
I ntron 5 RD-9g 7 c.942 JA >T 
I nlron 5 RD-1 053 c .942 3A>T 
I ntron 5 RD-2266 c .942+3A T 
lntron 9 RD-23f( c. I 5 1 I-9A>T 
I ntron 9 RD-599 c. 15 I I-9A>T 
I ntron 10 RD-64 c. I66 1+ 12G>A 
lntron 10 RD-70 c. I66 1+ 12G>A 
Intron 10 RD-238* c. I 66 1 + 1 2G>A ~ 
Intron 10 RD-34 7* c. l 66 1+ 12G>A 
Intron 10 RD-348 c . I 66 1 + 1 2G>A~ 
I nlron 10 RD-526. c .l 66 l 1 2 G>A~ 
Exon I I RD-34 7• c. l 666T>C 
I ntron 12 RD-526. c. l759 46A>T 
I ntron 12 RD- 1 053 ' c.1 759+46A>T 
* -Th..:s..: subject> rontaintwu polymorphisms 
~ -Till> chang.: was homo1ygnus 
Predicted 
Protein Change 
p.Vai265_GinJ 14dcl 
p.Val265_Gln3 14dcl 
p.Val265 Gln314del 
p.Vai265_Gln314del 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
p.Leu556Leu 
N/A 
N/A 
·-This subj..:c l C<llllains <> 11 <.: po l) morph ism and th..: "Fami ly ( ... mutation 
Novel 
No ' 
No' 
No' 
No ' 
No~ 
No 2 
No3 
No ' 
No' 
No3 
No3 
No3 
No4 
Yes 
Yes 
I - LcaLI1.F.S .. ,., a/ .. 1993. Liu.B .. ,., rd .. 1994. Froggau .N .J. er ,If .. 1995. Miya!.. i.M. I.' I a/. . 1995, Konisht.M. era/ .. 
1946. Thihmkau. . .. era/ .. 199(>. Mnslcin.( i . ,., ol .. 1996. Lu.S.l . er ol., 1996. Lu.S. L. era/ .. 1996. Pcnsotti.V. ,., ol .. 
I 997, \ ' i<:l.. \ . er a/ .. 1997. Wijnc·n . .l. er ol .. 1997. \ ' id .1\ . era/ .. 199::<. 13ai. Y.Q. era/., 1999. Bapat.B. V. ,., a! .. 1999. 
l'han.T. I .. ,·r a/ .. 1999. Curia.:vl .C. ,., ,If .. 1999. de L..:on. \I. P. ,., a/. 1999. Fmggati. N.J. etril .. 1999. L:unb..:rt i.C. Nal. 
1999. I in . .'< . 1'/ ol. I 999. L~ nt:h.II .T. ('/ a/ .. i9<JCl. S) ngal ... t'l ,,/., I tJ<J9. Wahlb.:rg.S. er ul. 19lJ9. Wang.Q. et a / .. 
1999. [k,ai .D.C. ,,, of .. ~000. 1- i,blgo.P. cr a/. 2000. Liu. r. ,., of .. ~(}Ofl. :'vl ani n.R.i-1 .1 cr a! .. 2000. Munll.:ra.M . i'/ a/ .. 
~000. 'nmura.S. ,., of .. 2000. Ot\\ay. R. er a/., ~IJIHl. P..:rr..:,.:pc.A. l'l of .. ~000. Pi~t nrtus,S . R. t 'l of .. ~000, 
13 isgaard. \1.1 .. ,·t o/ .. ~()() I . Caltk,.'L cr ,i/ . 200 I. ll ohthk t-F..:d.:r.l. . er of. ~()()I . .l a!..ubtm '!..a.:\. l 'l a/ .. 200 I. 
Kur / ,1\"" 1.C i .. ,., a/ .. 2()0 I. Samtl\\ it1. \\ .. S. ,., of .. ~001 . Funtl..:l\\ a. T. era/ .. ~002. K umt\"ki.G. er ,J!. ~002. 
ilbcrt. \1. ,., 11! .. 2002. \\ 'ahlh.:rg.S.S. <'i ,d. 2002. Yu.:n. '.T. ,., rd .. 2002. Wagnl'r.:\ . er a/ .. 2011.1. Fidds,.l.l. , ., a/. 
2004. Cai<b.T. ,., of. 2004 . .In~.( i . ,., ,J! . 2004. l.ag..:.P.A. ,., a/ .. 2004. \ 1anguld.F .. ,., a/.. ~004 . Pon1.d..: l...:on. ,., a/ .. 
2004. l l:unpl' i.ll. c'/ a / .. 2005.SI<lllllOI'i..l'll . .-\ .T. ,., .d .. 2005 
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Table 2.2: Polyrnorphisrns found in .l!Ll/1 
Ex on, Blood Base Change Predict~:d Novel 
lntron D A ID Protein Change 
Exon X RD- 147 c.655A cr· p.llc2 1 <.)Val No 1 
Exon H RD-H5 4 c.655A '-G p.llc21 <.)Val No 1 
Exon H RD- 1 052 c.655A .... G p.llc219Val No 1 
Exon H RD- 176<.) c.655A >G p . II e2 I <.) V a I No 1 
Exon H RD- 1913 c.655A ..- G p .II c2 I 9 V a I No 1 
Exo n 8 RD-2 164 c.655A>G p . II e2 I 9 V a I No 1 
I ntron 8 RD- 1 <.) 7 1 c.677+72G>T N/A Yes 
• -This change was h01no:r) go us 
I - Bucrsicddc . .I .M.el ai .. I<N5. Liu rt nl.. 1995. Moslcin.(1 . et ul .. 1996. Nystrom-Lahti.M. 1'1 a/ .. 1996. akaharn.M. 
1' / a/ .. 1997. Tom! inson.I.P. eta/ .. I '197. Hcrl~trlh.K . K . £'tal. . 1997. Wu.Y. et rd .. 1997. Shirnodaira.ll. eta/ .. 199R. 
Curia.:vt.C. eta/ .. 1999. Cihimcnli.C. <'I a/ .. I '199. Huttcr,P. <'I a/ .. 2000. ln t1m tc-Rivard.C. eta/ .. 2000. Montcra.M . et 
a! .. 2000. El li son.A.R. £'1 a! .. ~00 I. Furihata.M. eta! .. 200 I. Baldinu,P. <'I a/. 2002. Krajinovic.M. eta/. 2002. 
Kurzawski.(i . <'I a! .. 2002. Murnta.H. eta/ .. 2002. Palicio.M. eta/. 2002. Trojan.]. eta! .. 2002. Ward.R. eta/. 2002. 
Chcn-Shtoycnnan.R. <'I a! .. 2003. Kondo eta/ .. 2003. l\1athonncl.(i . £'1 a! .. 2003, Racvaara.T.E.I't a/. 2003. ln limtc-
Ri vard. . eta! .. 2003. Rcnkoncn.E. et .d .. 2003. Bagnoli ..:tal. .. 2004. 1-ludl..:r,P. eta/., 2004, Kim.J.C. el a! .. 2004. 
l.iu.S.R. <'I a/ .. 2004. Liu, . . R. ct al .. ~004. Rollinson.S. 1'1 a/.. 2004. Tournicr.l. eta/ .. 2004. Aprssos ..:tal. .. 2005. 
Bacani ct al ... 20115. Li.I.H. eta! .. 2005. Lee ..:1 al .. . 2005 . Oda ..:1 al ... 2005. Stanislawska-Sachadyn eta! .. 2005. 
JJam:traju eta! .. 2006. Song eta/. 200(1, Yu <'/a! .. 2006 
con't !'rom tabk: 2. 1 
2 - Cun ningham.J.M .. <'I a/ .. 200 I. Rajkumar.T. et ,d .2004. Hcgde I' I a/., 2005. Velasco eta! .. 2005 . .lung eta! .. 2006 
3 - Wij n..:n..l . ,., a! .. 1994. Wahlbcrg.S .S.I't a! .. 1997. F<ming.ton.S.M. 1'1 a/., 1 99~. P..:n:cscpr.A. el a! .. J99X, 
Desa i. D.C. <'1111 .. 2000 . 0 1\\ay.R. eta/ .. 2000. llolinsk i-Fcdc·r.E. eta! .. 200 I. Baldinu.P.el a! .. 2002. Kur/.awski.G . et 
a! .. 2002. Scarto//i.M . eta/ .. 2002. Chcn-Shtoymn;m.R.cta/. 2003. Ccdcrquist.K.et a! .. 2004. Liu.S.R. eta! .. 2004. 
Rajkumar. r. <'I a/ .. ~004 . p.:s.,os.A. el a! .. . 2005. Hcgdc ..:tal. .. 2005. l.c..: e1 ul .. 2005. Vclas..:o el ul .. 2005. Jung e1 ol .. 
100(1. \Vang ,., ul. ~006 
-1 - \Vchn..:r.!\11 . "'of. 19•J7. D..:o;;1i.JJ.C. ,., a/ .. ~000. Scott.R .. f .. ,·r a / .. 200 I. S..:an l//.t.M. <'I .d. 2002. Hendriks. Y. <'I 
ul .. 200J. t\udair c t a! .. 2006. Jung. ,., ul .. ~006 
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Fi2ure 2.3: Molecular Testin2 Breakdown by me and MSI Status: Flow chart 
illustrating samples tested based upon IHC and MSI status. 
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2.4 Discussion: 
All four samples from subj~cts that wen: at high family risk (i .e. AC I or AC2), 
and w~rc II IC dctici~nt for MSI 12 were found to carry the .\IS/1:! "Family C ' mutation . 
One ol' these subject's tumour was MSI low but still II IC n~gativ~ rl)r MSI 12. The other 
three samples were all MSI high. It should be noted that all lt)ltr subjects who were 
positive for the '"Family C" mutation came from families who were known fl·om the 
genetics clinic to segregate this mutation. 
Samples that were deficient for the MLH I protein ( 16) can be broken down into 
those that displayed hypermethylation of the MLH I promoter (9) and those that did not 
(7) (Figure 2.3). Only samples that were not hypermdhylated were sequenced. The 
hypermethylation status was determined by Dr. Roger Green's lab (Roger Green, 
Personal ommunication). Promoter hypermethylation cannot be easily determined to be 
either mono-allelic (benign) or bi -allelic (inactivating the gene). It was assumed at the 
time that any samples that were not of high familial risk and displayed methylation were 
bi-allelic. Al l of the samples that were deticient f()r MLH I and not methylated were MST 
high (7). One sample was from an individual with family AC I and MSI-H risk status but 
no mutation could be identified in the subject. 
Of the I 0 lSI 16-only dcticicnt samples, three were MSI high and seven were 
MSI low, or MSS (Figure 2.3). There were no subjects from high risk familic. among the 
MS I high samples, but there wen: two or intermediate risk as defined by the Revised 
Bethesda Criteria . One of these samples \\'as shown to contain an .\t/S//6 mutation that 
was round by another researcher \\Orking on the s:-~mc samples. The ,\lSf/6 mutation was 
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idcntificJ in a suhjcct \\·ho was negat ive rnr the I\ISII6 protein. M. I high anJ Bethesda I 
(Sec Appendix I). This mutation \\'as the duplication of an adenine hase at position ]514 
in c:wn () ( c.J5 l-klupA) \\ h ich caused a framcshi ft rcsulti ng in a prematun.: stop the 
codons downstream (p.Arg l972LysfsX5) (Amanda Dohcy. Personal Communication). 
This mutation has been previously described in two unrelated families as pathogenic 
(Wijnen eta/.. 1999, Plaschke eta/., 2004). o other mutations were identified in the 
other nine MSII6 negative sampks. 
There were severa l samples in the FCCR that were MSI high but IHC intact. 
Since the completion of this thes is' work IHC ha been pctformed for the PMS2 protein 
on these ·amplcs, and those deficient were then sequenced for PMS2 mutation by Dr. A. 
de Ia Chapcllc of the University of Ohio. Subsequently, two PMS2 mutations were 
identified in three subjects (Ban Younghusband, Personal Communication). 
Investigations into the MYH gene rc ponsible for MYH-associatcd polyposis (MAP) 
undertaken after the completion of this thesis ' work identified the MYH mutations. Two 
of these subjects were microsatellitc stable, while the other had no MSI data available. 
There were 18 other subjects that were heterozygous for known mutations in MYII 
(Roger Green, Ban Yow1ghusband, Steve Gallinger, Personal Communication). In 
addition to this ,\I/SH6 mutation, four more .. Family C" mutations, and one deletion of 
cxon eight of .\1S//:l (c.I277-'?_ IJ 86 '?del. p.Lys427_Gin462>GiyfsX4), a known 
founder mutation in the ewfoundland population. two mutations have been identified in 
PJfS:l and three subjccrs have been identi tied as homozygotes for know deleterious 
.\/}'//mutations. 
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Bas-:d upon th-: r-:sults or this study, it app-:ars that CRC caused by Lynch 
Syndrolll-: mutations in the N-:wroundland porulation corr-:latcs with a r-:ccnt USA 
population based study that found the total incid-:ncc or Lynch Syndrome was 2.2°1) of 
CRC. This \vas reported as the highest incidenCL' found in a USA population (llampclet 
a/., 2005). With the two PMSJ mutation carriers identified, the MSf/6 mutation, plus the 
nine lv/S/1] mutations found, the frequency of Lynch Syndrom-: in the NFCCR is 1.8(% of 
the 740 subjects with genomic DNA available. o mutations were found in the seven 
samples which were I HC deficient for MUll and not methylated. The majority ( 16 of 
23) of samples sequenced that displayed IIIC deficiency for MLH I, MSH2 or MSH6 
contained polymorphisms, regardless of family history or MSI status. 
There arc severa l reasons for not tinding a greater number of mutations in both 
the NFCCR and the Newfoundland population in general. First and most important is that 
this study selected people for MMR mutation testing only from information in the 
NFCCR database. This registry only includes individuals that had CRC in a specific time 
interval and agreed to participate in the study. The registry excludes those who declined 
to participate in the study, and also excludes those patients with Lynch Syndrome who 
may only have had extra-colonic tumours. Endometrial cancers arc more common than 
CRC in some kindreds and these would not have been included in the NFCCR 
(Quehcnberger eta/., 2005: Stuckless et u/., 2006). Also, patients who agreed to 
participate but subsequently died or were too sick to provide a blood sample limited 
testing again. These arc factors which cannot be O\"Crcome, and hopefully only exclude a 
\cry small percentage of Lynch Syndrome mutation ca rriers in the Newfoundland 
-3 7-
population. 
A second explanation li.)r the lmver than expected number of mutations identi lied 
is that there may he intronie mutations that acti\ate cryptic splice sites that were not 
sequenced due to distance from the intron. exon boundary. A novel intronic variant, 
c.1759 +46 T, \\'US found in .\/Sill in a subject who was a "Family ''mutation carrier. 
It is po. sihlc that this variant was introduccd via recombination or a spontaneous event 
onto the same chromosome as the "Family C" mutation in this particular family branch. 
This is likely a polymorphism, as previous cvidcncc has shown that two mutations in 
MSHJ. can cause a phenotype of F I (White. ide eta!., 2002), while this patient . bowed 
only a LS phenotype. If both variant ' w~.:rc inactivating the same allele the F I 
phenotype would not be present as wdl. It must be noted that thi , variant is possibly 
pathogenic, but doubtful. Another novel intronic variant was found in MLH I. 
c.677+72G>T, whose significance i still unknown. This subject's tumour wa IHC 
deficient for MLH I. MSI high, and not methylated. This subject was of Bethesda I risk 
status i nd icat i ng colorcctal cancer under the age of 50. Both of these i ntronic variants arc 
far from the splice sites but may activate cryptic splice sites. Future research in the form 
of expression and functional studies, arc needed before these variants can be con~idcntly 
classilicd as polymorphi. ms. 
Thirdly, there may be an upstream promoter mutation that would have been 
missed in routine se4uencing. There has pre\ iously been an .'vfU II promoter mutation 
dctcctcd in thc cwfoundland population by Gn.:cn eta!. (2003). Since thi. particular 
mutation \\as kno' n. it \\as screened for in all samples that wcrc scquencccllor MLH/ 
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but was not idcntilicJ in any subjects. 
Fourthly. IIIC staining that did not correspond with MSI data was rqx:atcd and 
some samples v .. erc reclassi lied. I r the correct I I IC status was known at the time of this 
thesis' work, more samples may haw been included, and the number of mutations 
identified may have increased. It must he noted however that ongoing testing of samples 
from the NFCCR using the updated information has identified no other mutations besides 
the MSJ-16 mutation previously mentioned in this thesis (Amanda Dohey, Personal 
Communication) 
Due to the c reasons, I suspect the incidence of Lynch Syndrome in the 
Newfoundland population is higher than I .8% making this study an underestimate of 
Lynch Syndrome in the Newfoundland population. For example, there were 7 samples 
that were MLH I deficient, MSI high, did not display hypermethylation and in which no 
mutation could be identified. There were also two samples which were deficient for 
MSH6 protein, MSI high and no mutation found. These samples indicate a mismatch 
repair dcncicncy of a currently unknown cause, and may include intronic variants 
affecting splicing which may be missed by cxonic sequencing. If mutations could be 
identified in these 9 samples high risk in addition to the 12 mutations found, the 
incidence of Lynch Syndrome in NFCCR would increase to 3.9%. 
As well as Lynch Syndrome. it is possible that there arc other cancer syndromes 
causing the increased CRC seen in the ewfoLmdland population. The three subject 
homozygous for ,\f}'/1 mutations indicated that at least some of this CRC burden is 
caused by MAP. All samples\\ ith genomic D1 A in the FCCR were tested for common 
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.\/}"//mutatinns \ ia an alkk specific PCR test. Sarnpks that cnntained a \ariant were 
then screened by Denaturing lligh Performance Liquid Chromatograpy (DIIPLC). a 
technique\\ hich compan.:s migration rates nf DNA through a gel and detect. variations. 
Those sampks \:vhich displayed variants were then sequenced to identify the DNA 
change. The possibility cannot be excluded that there arc novel genes causing CRC in 
Amsterdam Criteria l(tmilics via Familial Colorectal Cancer Type X (Lindor eta/., 2005). 
These would have bl!cn missed l!ntin:ly by this study. 
In the future, samples from this study which arc negative for MSH2, MLH I. 
MSI/6 and PMS2 mutations, at high family risk, and have tumours that arc MSS may be 
useful in genome wide scan studies for detection of novel CRC causing genes. While the 
high prevalence of CRC in ewfoundland is possibly the result diet and/or a population 
collection of modi lying alleles or low pcnctrancc mutation acting together in addition to 
Lynch Syndrome, there may be novel genes responsible for Familial Colorectal Cancer 
Type X phenotype. There have been 15 cases in the NFCCR classiticd as ACI or ACII 
and without MMR deficiency (MS ) indicating Familial Colorcctal Cancer Type X 
(Green eta/., 2007). 
] . 4.1 ,'v/utution or Polrmomhism? 
___ A recurring issue with the DNA sequencing data generated from this project 'vvas 
that a significant number of 'variants identified wen.~ ofunknown dfect. Variants that 
\\'ere found could not easily be interprctl!d as pathogenic or benign. Otten. no other 
family members were aYailablc for scgrl!gation analysis. Each variant was searched lor in 
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the litcratun.: individually and it is very likely that some data were missed. The only 
functioning MMR ,·ariant database at the time, was hosted by the International Society 
for I kreditary Gastrointestinal Tumours (lnSiGIIT) on their \VL'bsitc. This database 
includes submitted data only. lacking the majority of,·ariant information concerning LS 
in the published literature. Thcn:li.Jn.:, it was decided to construct a database or all 
published MMR variants as part of this thesis. 
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Chapter 3 
3.0 Mismatch Repair Variant Database 
3.llntroduction: 
During mutation screening, missense and other changes were found which could 
not be easily classified as either pathogenic or polymorphic. Each ofthcse unclassified 
variants (UVs) required a search in the Lynch Syndrome variants database from 
\\ \\'\\·.insigh t-group.org or an extensive review of the published literature if the genomic 
variant was not listed in the database. The InSiGHT database is a compilation of 
submissions of variant data only. While it contains numerous unpublished variants in 
addition to those published, the submission-only nature of the database means it is largely 
incomplete. A review by the Human Genome Organisation Society (HUGO) was 
completed in 2002 on MMR genes MLHI and MSH2 (Mitchell eta/., 2002). This study 
reviewed all papers published up to and including December 31st 200 I and contained all 
published variants to this date as well as all the unpublished variants in the InSiGHT 
database. Upon searching for another database or review which was both current and 
compn:hensivc, it was found there was none. 
To provide a resource for ourse lves and for other Lynch Syndrome researchers, 
the task of constructing a complete, current and comprehensive Lynch Syndrome variant 
database was undertaken. For the purpose of this thesis. a variant is dctined as a genomic 
alteration reported in the literature which is different from the refen:ncc sequence from 
--+2-
cnscmbl ror each gene. The database \\'as to consist or all variants published in the 
mismatch repair genes .HU II . . \/S/1] and .\IS/In\\ hich were estimated to account ror 95-
100° o of all knm\'11 Lynch Syndrome variants. En:ry paper that was published on each or 
these genes was re\ iewcd, and any paper that was found to contain or possibly contain a 
variant was catalogued and collected for rd\.:renee and fLu·ther rev icw (so as not to miss 
any potential data). From this catalogue, a variant database was dL:velopcd with an 
accompanying website allowing online access. 
For the purposes of this thesis, mutation is de lined as a genomic change from the 
reference sequence, know to cause LS. A variation/variant is defined as a genomic 
change from the reference sequence of unknown or unclear significance. A 
polymorphism is defined as a genomic change from the reference sequence which is not 
associated with any effect. 
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3.2 :vlaterials and Methods: 
Th~: three major mismatch r~:pair g~:n~:s, ,\/U II .. \IS/12, and MS/16 arc sugg~:st~:d 
to account li.1r 95-100° o of all\ ariants <.kt~:ct~:d in Lynch Syndrome cases, making these 
genes the ob\·ious choice for the variant database. sing Reference Manager . I 0, 
PubM~:d was searched for each of these gene names, as well as each alternative name 
found using NCB! EntTez Genc. For ,"v/S/1:!: k/S/!2. lt/'v/S/12. FCC/. COCA!. and 
HNPCCI were used. For ML/-11: .'v/L/11. hMUfl . FCC2. COCA2. and HNPCC2 were 
used. For A'fS/-16: MS/-16. hMSH6. CTBP. 1/S/IP. and HNPCC5 were used (Table 3.1 ). 
This thesi ' work reviewed all the publications up to August 15'11 , 2005 but the database 
has been maintained and updated since by Amanda Dobey. 
Table 3.1: Alternative MMR 2ene names 
Gene Keywords 
/'vi L/-1 I MLI-ll , hMLIII, FCC2*, COCA2* and H PCC2* 
MSH2 MSH2, hMSH2, FCC I*, COCA I* and HNPCCI * 
MSH6 MSl-16, hMSH6, GTBP, HSAP* and H PCC5* 
PMS2 PMS2, hPMS2, HNPCC4*, PMS2CL* and PMSL2* 
* -T ht.:Sl' namc' an.: no longer currcnl and did not rcsult in any publication' 
All gene searche. were then combin~:d into a single list using Reference Manager 
includ ing complete rcfercnc~: , PubMcd hyper! ink and abstract. Each abstract was then 
reviewed careful ly for indications ofsequ~:nce variants. lf this was unclear from the 
abstract alone, the paper was read in PDF form if available, or it was marked to be 
acquired in print form . All reference. that either stated they contained \ ariant data or 
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could possibly contain data or human M MR 'ariants m.:re then combined into a new 
reference list in which each paper was either dm\'llloaded in PDF format or acquired in a 
hard copy. numbered and assigned a unique rekrcnce ID number in Reference Manager. 
Each paper was then reviewed l'ully ltn variants. A small pen:cntage (- 6°'o) of papers 
were in a language other than English. Some ol'thesc listed the variants in proper 
nomenclature and were able to be transcribed directly into the database. Others required 
the assistance or foreign language translators who volunteered their time. 
For each variant reported, the nucleotide number, codon, and base was confirmed 
against the published sequence at \V\\ '' .enscrnhl.t)rg,, with any deviations noted in the 
database. Secondly, the putative protein change, if appl ieablc was checked against the 
published sequence and any errors noted. After errors were noted, the variant was 
recorded in the database according to the most recent and updated nomenclature available 
online at: hllp: "'"" \\ .gcnornic. uninlelh.edu.;m mdi: mutll\llllen,. This nomenclature is 
compiled and maintained by the Human Genome Variation Society (HGVS) and is 
updated regularly. Due to the constant change in the nomenclature, there arc frequent 
differences in the published literature and the HGVS recommendations depending on the 
publication date. Previously correct nomenclature was updated to the current standard 
and not noted in the database, as the majority of references before the year ::woo usc 
nomenclature that is outdated and equivocal. Fortunately, most recent publications usc 
current nomenclature which is important lor maintaining a standard for comparison or 
current and future references. 
--+5-
3.3 Results: 
PubMed \\'as searched ltlr publications by each of the alternate names l(lr the three 
major MMR genes. It was found that some of the older names I(H· each of the genes did 
not yield any results, so they were omitted from future searches. The numbers presented 
here arc current up to June 27'". 2007. For ;\/SIC, only the search terms /v!SII:! and 
Mv!SII:! were used yielding 2217 abstracts, l()r MU II, only the search terms ML H I and 
hML/11 w~:re used yielding 2394 abstracts. For MSH6 it was found that in addition to 
MSf/6 and hMS!-16, the original name of the gene, CTBP also yielded results, requiring 
the inclusion of this search term. For MS!-16 there were 753 abstracts. 
In total, 1306 papers have been identil~ed which contained mutation information 
and were reviewed thoroughly for MMR mutations. This includes 579 for ML!-11, 559 for 
MS!-12, and 198 for MSf/6. There were 942 unique variants for ML!-11. 924 unique for 
MS!-12 and 28 1 unique for MS!-16. The current updated version of the database is available 
on line at: http : ''" \\ .lllt.'d.n1un.ca rnmn ;~riants, a screenshot of the home page is seen in 
Figure 3.1 . Genomic variant classification and distribution is summarised in Figures 3.2-
3.9. Sine~: 2005, the database has been updated and maintained with the addition of 
variants !"rom P.'v!S2. 
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Mutat1ons 1n speofic DNA m1smatch repa~r (MMR) genes cause Lynch syndrome (often called hereditary 
non-polypoSis colorectal cancer), wh1ch is characterizt!d by a predisposition to colorectal cancer and 
other primary cancers. The colorectal tumours are charactenzed by an t!arly age of onset and are 
found predominantly in tht! proximal colon. 
At least four MMR genes are known to cause Lynch syndrome when mutated - HLH1, MSH2, MSH6 and 
PMS2. S1nce 1993, hundreds of distinct genomiC variants have been identified throughout tht!se genes, 
and thert! art! few mutation hot spots. A targe numbt!r of these altt!rations art! missense variants, 
intronic vanants and synonymous changes. 
Dt!term1ning the patholog1cal significance of these variants is difficult; one approach 1s to rev1ew the 
published litt!raturt! to dt!termine if others have idt!ntified the variant in QUt!stion and 1n what d1n1cal 
c~rcumstances rt has been observed. To assist in th1s process we have catalogued all alterat1ons found 
'" these MMII. gt!nes 1n the literature. 
I ncluded in thi5 database art! only thost! variants wh1ch have been published in peer-rev1ewed journals. 
We have not yet attempted to catalogue 11ariants which have ncrt bt!en published o r found on other 
websites (e.g. InSiGHT). We have provided a means for databast! ust!rs to subm1t unpublished vanants 
and, 1n the future, we w1ll 1ndude unpublisht!d data in a st!parate searchable database. 
Disclaimer: This database is meant to be a catalogue of known MMR gent! variMts. We have made no 
attt!mpt to lntt!rpret the pathological sign1f1cance of theSt! vanants. Howt!ver, dur1ng tht! course of 
rt!VIt!Win<;J rt!levant articles we altered the names of many publ1shed vanants to rt!flect the recent 
rt!commendations of the HGVS. 
There are currently 1850 d1st1nct entries 1n our databaSt!. 
Last updated on 31/05/2007 
Fi2ure 3.1: Screenshot of the Mismatch Repair Genes Variant Database Website 
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3.3.1 Exonic Distribution of Unique Variants by Gene: 
A "unique variant" was defined as a singular genomic DNA deviation from the 
reference equence. Regardless ofhow many times it had been reported, it is recorded 
once in these figures. The distribution of unique variants in MLHJ showed a skewed 
distribution. Ex on 12 had the highest number of variants with 58 unique variants reported 
while exon 16 had the second largest report of unique variants at 54. Variants in exons 7 
and 15 were rare with 25 and 22 unique variants respectively (Figure 3.2). When 
comparing the distribution of unique variants and the size of the exons (Figure 3.3), it is 
noted that exon 7 had the most reported variants for its size (58.14 variants/ ] 00 bases), 
while exon 4 had the second highest (55.41 variants/100 bases). Intronic variants were 
common, with introns 8, 9, 13 and 15 most frequently containing variants. 
MSH2 displayed the most variants in exon 3 with 84 unique entries. Exon 12 had 
the next highest number of variant with 66, followed by exon 13 with 62 (Figure 3.4). 
When comparing the number of unique variants for the size of the exon, it i een that 
ex on 11 shows by far the most changes with 53.06 variants per 100 bases, while the final 
exon in MSH2, exon 16, has the least variant at 6.32 variants per 100 base (Figure 
3.5). Overall, the distribution of variants wa more regular than those of MLHJ when 
comparing unique variants her l 00 bases of exon. Tn general, intronic variants were 
fewer in MSH2 as compared with MLHJ . 
Variants in MSH6 showed an expected kewed distribution of unique variants in 
exon 4 due to its large relative size. Exon 4 has 112 individual variants, while the next 
most heterogenous exon, exon 5, only contained 27 unique variants (Figure 3.6). Thi can 
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be explained by the relatively large size of exon 4 which has 2645bp when compared to 
the other exons which range from 82bp to 473bp in size. The next largest exon, exon 1, 
only has 473bp. Wben comparing unique variants per lOObp, exon 4 is not found to be 
more frequently changed (Figure 3.7). 
3.3.2 Distribution o( Unique Variants by Tvpe: 
Differences between the types ofvariants seen in each ofthe different genes is 
apparent as well. Missense changes were slightly more common in MSH6 and MLH 1 
accounting for 27% and 24% of unique variants respectively, and only 17% of MSH2. 
Nonsense changes were evenly distributed among all three genes with 11 % in MSH6, 7% 
in MLH1 and 10% in MSH2. Insertions and deletions were slightly more common in 
MSH6 (37%) than MLH1 (22%) and MSH2 (25%). Silent variations only accounted for 
9% of MSH2 and of MLH1 changes, yet were responsible for 21 % of all MSH6 changes. 
Unique variants that affected proper splicing were common in MLH 1, accounting for 13% 
of variants, but were less common in MSH2 at only 6%, and very rare in MSH6, 
accounting for only 2%. Large genomic rearrangements (deletion or duplication of one or 
more exons) were very common in MSH2 (33%) and MLH1 (25%) but were virtually 
absent from MSH6 (2%). This is all summarised in Figures 3.8-3.1 0. 
Upon examination of the percentage of transitions versus transversions for the 
three MMR genes, it was found that transitions (purine to purine or pyrimidine to 
pyrimidine changes) outnumbered transversions (purine to pyrimicline, or pyrimidine to 
purine changes) for all three genes, as expected. While there are twice as many possible 
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transversion changes due to the greater number of bases that can be substituted, 
transitions are generally more commonly found in genes. This is due to several reasons, 
including transibon changes generally resulting in more conserved amino acid changes 
due to wobble in the genetic code allowing for silent mutations which are less likely to 
disrupt function, C->T transitions occurring frequently in methylated CpG islands 
concentrated in promoter regions, and differential DNA repair systems which repair 
transversions more readily than transitions (Strachan and Read, 2004). The results arc 
summarised as follows: for MLHJ the breakdown was 54% transitions and 46% 
transversions; for MSH2, the breakdown was 55% transitions and 45% transversions; for 
MSH6, the breakdown was 60% transitions and 40% transversions. 
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3.4 Discussion : 
There ,,·ere a number of\ ariants that wen:: l'r:cquent in the database. For example 
the Ne\\ ll.nmdland "Family C'mutation in ,\/S/1:! (c.9-l2+3A'-T. p.Vai265_Ciln314dcl) 
has been reported in over 70 publications and this mutation has been previously reported 
to occur li·equently de 1/0\ '0 (Desai eta/ .. 2000). It is almost certain that some of these 
entries arc !rom either the same lnmily reported multiple times, or multiple seemingly 
distinct families sharing a common, but unknown, founder It is impossible to determine 
from the literature what percentage of reported mutations arc unique occurrences or the 
descendants of a single event. 
Large genomic rearrangements arc reported to be more common in MSH2, but 
there arc similar unique changes between MUll (33% of unique mutations for MLH I) 
and MSH1 (25% of unique mutations for MSH2). The rarity of large genomic 
rearrangements in MS!-16 (2% of unique mutations for MSH6) could be due to the fact that 
it is less common for MS!-16 to under go genomic rearrangement, or probably due to 
minimal testing done on MSf/6 regarding rearrangements. Now that there is an MLPA kit 
avai lable for testing of all exons of MS!-16 , the reported incidence of genomic 
rearrangements in J'l-15116 may increase. 
The number of intronic variants reported is most definitely under observed due to 
the f~1ct that full introns arc not normally sequenced. lntrons arc generally massive 
compared to the coding regions of genes, and since they arc not expressed, variants in 
these regions arc unlikely to be pathogenic. lntronic ,·ariants that interfere with splicing 
arc notable exception. to this. but most splicing mutations occur at the splice site 
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consensus sequences bonkring exons, "hich arc al\\ ays sequenced due to their proximity 
to the exon. 
During the construction of' the :VIi'vtR \ariant database, it was noted that a 
significant number or the reported alterations in the published literature were in error. This 
was more common in older papers {prior to 2000), but many recent papers carried 
signilicant errors as well. Mistakes in nucleotide and codon numbering in the paper 
compared to the correct reference were the most common. Other common cn·ors included 
incorrect numbering of new top codons generated by framcshifts or amino acid changes 
in missense mutations. All of these mistakes were the result of human error and arc 
recorded in the comments section or the database for each error. Previously correct 
nomenclature wa. modified to the current standard, and was not noted in the database. 
Occasionally, gene names were mixed up and while a particular variant wa labelled a 
being in one gene, examination of the data showed the variant to actually be in another 
gene. Errors in the published literature were sometimes, but rarely addressed in errata 
published after the initial publication. 
Errors in peer reviewed publications imply they were missed by the original 
authors and reviewers as well as by publication editors. This points to the need for 
reviewers and writers of manuscripts to get back to basics and to check simple data 
output. Well-published authors in Lynch yndromc were no exception to committing 
nomenclature errors. The literature rcvie\\' for this database highlights the importance or 
carefully checking and correcting variant and mutation information during the publication 
process . These errors should ha\'c been corrected bct'orc the paper was even submitted, let 
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alon~ publish~d. Corr~spond~m:~ autllllrs wer~ som~times eontact~d if th~ ~rror 'v\as 
cryptic. but k\\' r~sponded . 
The variant database has bccom~ a 'v~ry popular tool since it has b~cn available 
online. Th~ site has rccci\ ~d many positive emails from r~searchers around the globe and 
has had m·~r I 3,000 visits during its liktim~. There arc links to the database on the 
lnSiCiiiT group's w~bsite (in addition to their own databas~). as well as the IIC1VS list of 
human variant databases . The database will be maintained and updated monthly for new 
variants and current nomenclature by the lab of Dr. Ban Younghusband and Dr. Michael 
Woods. It appears that this new MMR database will be the principal resource for 
researchers and clinicians who require information concerning published Lynch Syndrome 
variants. 
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Chapter 4 
4.1 Conclusions 
___ The overall incidence of Lynch Syndrome fi.>Und in this study of the FCCR was 
I. X1% or colorecta l cancer cases. A I.X% incidence rate concurs with previous studies 
placing estimated incidence of Lynch Syndrome between 2-6% of CRC. There were 
severa l subjects whose tumours had molecular characteristics of LS (MSI and/or IHC 
negative for MM R protein) but in which no deleterious mutation could be idcntiticd. In 
addition , this study only examined in incidence of LS in CRC, excluding extra-colonic 
tumours that arc frequently associated and sometimes more prevalent in LS. Due to these 
factors the author believes the reported 1.8% incidence LS found in this study is an 
underestimate of the true incidence of LS in the province. ___ _ 
___ The MMR variant database developed and used in this study proved to be an 
invaluable resource. It allowed the rapid identification and review of all previously 
published literature concerning LS variants. Searching the database for variants identified 
in this work, particularly intronic variants of unknown significance, allowed easy access 
to previous investigations into pathogenicity. This allowed for the efficient labelling of 
variants as polymorphisms. or pathogenic mutations. The initial creation of the database 
was labour-intensive and time-consuming hut once established and the expertise 
developed, maintaining and updating v.:as \'ety efficient. ___ _ 
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Appendix 1: Bethesda and Revised Bethesda 
Criteria 
Bethesda Criteria (Rodri~uez-Bil;!aS eta/., 1997): 
ny on ~.: of th ~.:s l! cond itions may bl! ml!t: 
I. lnd i\ idual s with cancer in famil ies that meet th t..: Amsterdam Criteria 
2. Individuals with two II PCC-rclated cancl! rs, including synchronous and metaehronous 
co lorectal cancl!rs or assoc iated extracolonic cancers* 
3. Individuals with eolorectal cancer and a ti rst-degree relative with colorcctal cancer 
and/or II PCC-rclated extracolonic eancl!r and/or a colorectal adenoma; one of the 
cancers diagnosed at age <45 y, and the adenoma diagnosed at age 40 y 
4. Individuals with colorectal cancer or endometrial cancer diagnosed at age <45 y 
5. Individuals with right-sided colorectal cancer wi th an undifferentiated pattern 
(solid/cribriform) m histopathology diagnosed at age <45 yt 
6. Individuals with signet-ring-cell-type colorectal cancer diagnosed at age <45 yi 
7. Individuals with adenomas diagnosed at age <40 y 
"'Cndo mt.: tria l, o ~ar ian , gastr ic. hcpa tobil ia ry, or small -bo we l .: anccr or tra nsi t io nal ce ll ca rc inoma of the 
r..:na l p..: lvis or un.: t..:r. 
tSo lid/cnlmrorrn defined as poorl y d itTc n.:n tia tcd or und ifr.:rcnt iall:d carci noma compose d or irr..:gu la r. so lid 
shn :ts o r largc eosin ophi lic cells and contai ning small gland- like spaces . 
t Co mpn sed o r ·50"., >ig nct ring ce lls . 
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Revised Brthesda Guidelines (Umar t!t a!., 2004) 
Tumors fium indi\'iduals should be tested f()r MSI in the f()llowing situations: 
I. Colorcctal cancer diagnosed in a patient who is less than 50 years of 
age. 
2. Presence or synchronous, rnctachronous colorcctal, or other I IN PCC associated 
tumors.* regardless of age. 
3. Colorectal cancer with the MSI-11"1' histologyt diagnosed in a patient who is less than 
60 years ofagc.~ 
4. Colorectal cancer diagnosed in one or more tirst-degree relatives with an HNPCC-
related tumor, with one of the cancers being diagnosed under age 50 years. 
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with 
HNPCC -related tumors, regardless of age. 
"Hc:rcditary rwnpolypusis culorc:ctal cancer (HNPCC)-n:latcd tumors inc lude ..:u lorectal. cndomt.:trial. 
stoma<.:h. ovarian. pan..:rc:as. ur<.:tcr and rcnnl pt.:lvis.biliary trnt:t. and brain (usually gli ob lastoma as seen in 
Turcot syndrome:) tumors . sebaceous gland adl!nnnws and k<!ratoacanthomas in Muir Torre sy ndrome. and 
<.:an;i noma of the: ~mall bowt.:l. 
"I"M SJ-H microsatl!ilite instability hi gh in tumors rt.:fers to ..:hangt.:s in two or more of the five Na ti onal 
C'anct.:r lnstitute-rccom mend..:d panels uf micrusatt.:llitc markers. 
!Pr..:sen.:.: oftumor infiltrating lymp hocylt.:s. Crohn's- lik e lymphocytic rca<.:tion. mucinous/signet- ring 
difft.:n: nt ia tiun . or mt.:dullary grow th patt..:rn. 
~Th..:rc wa~ no CtlllScnsus anrong tht.: Workshop participnnts on wh..:thl!r tu in<.:lude the age criteria in 
gui de line 3 a hove ; participants vo ted to kt:cp Jess than 110 y..:a rs of age in tht.: gui d..: lines. 
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Appendix 2: Sequencing Primers 
MLH I Primers· .
am~: Locus s~qu~ncc 5'-'3' 
EIFA EXON I AGGCACTGAGGTTCIATTCiGC 
EIRB EXO I TCGTAGCCCTT AGTGAGC 
E2FA EXO 2 AA TAT(jTACATTAGAGTAGTTG 
E2RB EXO 2 CAGAC1AAAGGTCCTGACTC 
EJFA EXON 3 AGAGATTTGGAAAATGAGTAAC 
E3RB EXO 3 ACAATGTCATCACAGGAGG 
E4FC XON 4 GACCCAGCAGTGAGTTTTTC 
E4RB EXO 4 GATTACTCTGAGACCTAGGC 
E5FA EXON 5 GATTTTCTCTTTTCCCCTTGGG 
E5RB EXON 5 CAAACAAAGCTTCAACAATTTAC 
E6FA EXON6 GGGTTTTATTTTCAAGTACTTCTATG 
E6RB EXON 6 GCTCAGCAACTGTTCAATGTATGAGC 
E7FA EXON 7 CTAGTGTGTGTTTTTGGC 
E7RB EXON 7 CATAACCTTATCTCCACC 
E8FC EXON 8 CAGCCATGAGACAATAAATCC 
E8RD EXON 8 GAAGCATAAAACAAGCCTGTG 
E9FC EXON 9 AGGACCTCAAATGGACCAAGT 
E9RD EXO 9 GGTCCCATAAAATTCCCTGTG 
EIOFA EXON 10 CATGACTTTGTGTGAATGTACACC 
E I ORB EXO 10 GAGGAGAGCCTGATAGAACATCTG 
Ell FA EXON II GGGCTTTTTCTCCCCCTCCC 
EIIRB EXON II AAAATCTGGGCTCTCACG 
E12FE EXO 12 ACAGAAGCTTGATGCATTTC 
-7 1-
E12RF EXON 12 ACiACi t\ CiATGCAACiTCiA TTCA 
E12FG EXO 12 t\ TAC':\C1ACTTTGCTACCACiGACT 
E 12 RII r:xo 12 Ci<JGGTTCiCTGCJAAGTACiGTC 
EIJ RC EXON 13 TCiA TGCT A TTGTGGCjTT AGT 
E UF EXON 13 TCiC AACC C ACAAAA TTTGGC 
EI ~FC EXO 14 A TTGGTGTCTCT AGTTCTC,GT 
E14RD EXON 14 ACTACCTTCATGCTGCTCTC 
EI5FC EXON 15 CCAACTGGTTGTATCTCAAGCAT 
E15RB EXON 15 CGGTCAGTTGAAATGTCAG 
EI6FA EXO 16 CATTTGGATGCTCCGTTAAAGC 
EI6RB EXON 16 CACCCGGCTGGAAATTTTATTTG 
EI7FA EXO 17 GGAAAGGCACTGGAGAAATGGG 
E17RB EXON 17 CCCTCCAGCACACATGCATGTACCG 
E18FC EXON 18 AGTCTGTGATCTCCGTTTAG 
E18RD EXO 18 GATGTATGAGGTCCTGTCCTAGT 
E19FA EXON 19 GACACCAGTGTATGTTGG 
E19RB EXO 19 GAGAAAGAAGAACACATCCC 
E19FC EXON 19 GAGGCTTATGACATCTAATGT 
E19RD EXON 19 AAGAAATTATGTTAAGACACATCT 
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llSf/2 Primers· 
am...:: Locus S~:q liO..:IlCI.: 5'- ~ .1' 
IIE1FC EXON 1 GGCGGGAAACAGCTTAGT 
II E1RD EXON 1 AAGGAGCCGCGCCACAA 
11 2A EXON :2 CTTGAACA TCiTAATATCTC AAATC 
11E2 Rl3 EXON 2 CCCATTCTACTATCACAATCT 
II EJFC EXON 3 CATAGAGTTTGGATTTTTCCTTTTTGCT 
II EJ RD EXON 3 CTAGGCCTGGAATCTCCTCTATCACTAG 
HE4FA EXON 4 ATTCCTTTTCTCATAGTAGTTT 
II E4RB EXON 4 TTGAGATAAATATGACAGAAATAT 
HE5FA EXON 5 CCAGTGGTATAGAAATCTTCG 
HE5 RC EXON 5 TACCTGAAAAAGGTTAAGGGC 
HE6FA EXON 6 GAGCTTGCCATTCTTTCTAT 
HE6RB EXON 6 GGTATAATCATGTGGGTAAC 
HE7FA EXON 7 CTAAAATATTTTACATTAATTCAAG 
HE7RB EXON 7 ATGTGTCCTAAGAGTGAGTC 
HE8FC EXON 8 GATCTTTTTATTTGTTTGTTTTAC 
HE8RD EXON 8 AATATTACATCCACTGTCCAC 
HE9FA EXON 9 GTCTTTACCCATTATTTATAGG 
II E9RB EXON 9 GTATAGACAAAAGAATTATTCC 
HEIOFA EXON 10 GTGAGTATGTTGTCATATAATAA 
HE I ORB EXON 10 GCATTTAGGGAATTAATAAAGG 
11 El1 FA EXON II CATTATTTGGATGTTTCATAGG 
11 El1RB EXO 11 CATGATTTTTCTTCTGTTACCA 
I! El2FC EXON 12 TGTAAATTAGGAAATGGGTTTTGA 
HE12RB EXON 12 CAAAACGTTACCCCCACAA 
11 El3FA EXON 13 CTTGCTTTCTGATATAATTTGTT 
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II E I JRB EXO 13 CATCiACiAATCTGC AAATATACT 
liE 1--+F,\ EXON l..f CiCiCAT.'\ TCCTTCCCAATGTAT 
IIE I..fRB EXO. l..f ACITAACITTTCCCATTACC AACI 
II E I SFA EXON 15 TCTTCTCATGCTGTCCCCT 
IIE I SRB EXON 15 ATAATAGAGAAGCTAGTTAAAC 
II E16FC EXO 16 CTCATGGGACATTCACATGTGTTTCA 
liE 168 EXON 16 TTAAGTTGATAGCCCATGG 
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